Market Performance - Major US stock indices closed lower due to weak non-farm employment data, reinforcing expectations for a Federal Reserve rate cut [1][2] - The Dow Jones Industrial Average fell by 0.48% to 45400.86 points, the S&P 500 decreased by 0.32% to 6481.5 points, and the Nasdaq dropped by 0.03% to 21700.39 points [1] - European indices also closed down, with Germany's DAX down 0.73%, France's CAC40 down 0.31%, and the UK's FTSE 100 down 0.09% [1] Employment Data - The US added only 22,000 jobs in August, significantly below the expected 75,000, with an unemployment rate of 4.3%, marking a 0.1 percentage point increase for the second consecutive month [2] - Job growth was primarily in the healthcare sector, which added 31,000 positions, while manufacturing, wholesale trade, and government sectors saw losses of over 10,000 jobs each [2] - Analysts suggest that tariff policy uncertainties are a major factor contributing to the labor market's weakness [2] Gold Market - International gold prices reached a new high, with COMEX gold futures rising by 0.92% to $3639.8 per ounce [3] - In August, gold ETFs saw a net inflow of $5.5 billion, mainly from North America ($4.1 billion) and Europe ($1.9 billion) [3] - The price of gold has increased by 31% year-to-date, driven by a weak dollar, geopolitical tensions, and continued inflows into gold ETFs [3] Oil Market - US oil prices fell sharply, with the main contract down 2.38% to $61.97 per barrel, and Brent crude down 2.06% to $65.61 per barrel [4][5] - The decline in oil prices is attributed to rising expectations of increased production from OPEC+ and concerns over economic recession [5][6] - OPEC+ is considering further increasing oil production to regain market share, having already raised output by approximately 2.5 million barrels per day since April [6]

Market Overview - Major US stock indices collectively declined due to weak non-farm employment data, which reinforced expectations for a Federal Reserve rate cut [1][4] - As of the close, the Dow Jones Industrial Average fell by 0.48% to 45400.86 points, the S&P 500 decreased by 0.32% to 6481.50 points, and the Nasdaq dropped by 0.03% to 21700.39 points [2] Employment Data - The US Labor Department reported that 22,000 jobs were added in August, with an unemployment rate of 4.3%, marking a 0.1 percentage point increase for the second consecutive month [4] - The job growth was primarily in the healthcare sector, while manufacturing, wholesale trade, and government sectors saw significant job losses [4] Gold Market - International gold prices reached a new high, with COMEX gold futures rising by 0.92% to $3639.8 per ounce [6] - In August, gold ETFs saw a net inflow of $5.5 billion, mainly from North America and Europe, while Asia experienced outflows [6] Oil Market - Crude oil prices fell significantly, with US oil main contract down 2.38% to $61.97 per barrel and Brent crude down 2.06% to $65.61 per barrel [8] - The decline in oil prices is attributed to rising expectations of increased production from OPEC+ and concerns over economic recession [9]

These once high-flying stocks no longer seem to have promising prospects.Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.Take Teladoc Health (TDOC 2.10%) and Sarepta Therapeutics (SRPT 0.65%). These two healthcare companies have lagged the market this year, but even at their current levels, they don't look particularly attractive. Here's why investors should stay away from the ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, during the period from June 22, 2023, to June 24, 2025 [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks around the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and suspending shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding acute liver failure risks led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against Sarepta and must file a motion for lead plaintiff by August 25, 2025, to represent other class members [5].

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS, for treating Duchenne muscular dystrophy [3]. Allegations and Misleading Statements - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events would lead to halted recruitment and dosing in trials, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory scrutiny and halted recruitment, the stock price fell by $4.18 per share, or 7.13%, closing at $54.43 [4]. - A second patient death was reported on June 15, 2025, leading to a significant drop of $15.24 per share, or 42.12%, closing at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [4].

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=163007&from=4CLASS PERIOD: June 22, 2023 to J ...

Core Viewpoint - A securities class-action lawsuit has been initiated against Sarepta Therapeutics due to safety concerns and regulatory setbacks related to its gene therapy, ELEVIDYS, alleging that the company misled investors about the treatment's safety and efficacy [1]. Company Developments - The lawsuit claims that Sarepta misrepresented ELEVIDYS as a safe and effective treatment with a clear path to regulatory approval, which has led to significant investor losses [1]. - The European Medicines Agency (EMA) rejected ELEVIDYS on July 24, 2025, after a trial involving 125 children showed no significant improvement in movement compared to a placebo, severely impacting Sarepta's European market expansion plans [3]. - The timeline of disclosures indicates that Sarepta's stock price has faced multiple declines due to safety and regulatory news, including a patient death in an ELEVIDYS trial reported on March 18, 2025, and a subsequent investigation by EU authorities [6]. Legal and Investigative Actions - Hagens Berman, a national shareholder rights firm, is investigating claims on behalf of investors who suffered substantial losses and is encouraging individuals with relevant information to come forward [4][5]. - The firm has set a deadline of August 25, 2025, for investors to be considered as Lead Plaintiff in the lawsuit, which covers the class period from June 22, 2023, to June 24, 2025 [2].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall by more than 40% on July 18, 2025 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Sarepta investors affected by alleged securities fraud between June 22, 2023, and June 24, 2025 [1]. - The complaint claims that Sarepta made false statements regarding ELEVIDYS, including significant safety risks and failures in trial protocols to detect severe side effects [2]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].